INBS vs. CTSO, MBOT, TELA, APT, ECOR, APYX, INO, TMDIF, MODD, and SPAI
Should you be buying Intelligent Bio Solutions stock or one of its competitors? The main competitors of Intelligent Bio Solutions include Cytosorbents (CTSO), Microbot Medical (MBOT), TELA Bio (TELA), Alpha Pro Tech (APT), electroCore (ECOR), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), Titan Medical (TMDIF), Modular Medical (MODD), and Safe Pro Group Inc. Common Stock (SPAI). These companies are all part of the "medical equipment" industry.
Intelligent Bio Solutions vs.
Cytosorbents (NASDAQ:CTSO) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Cytosorbents has a net margin of -49.47% compared to Intelligent Bio Solutions' net margin of -323.79%. Cytosorbents' return on equity of -118.54% beat Intelligent Bio Solutions' return on equity.
In the previous week, Intelligent Bio Solutions had 5 more articles in the media than Cytosorbents. MarketBeat recorded 12 mentions for Intelligent Bio Solutions and 7 mentions for Cytosorbents. Intelligent Bio Solutions' average media sentiment score of 0.74 beat Cytosorbents' score of 0.35 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.
Cytosorbents presently has a consensus target price of $4.67, suggesting a potential upside of 366.67%. Given Cytosorbents' stronger consensus rating and higher probable upside, research analysts clearly believe Cytosorbents is more favorable than Intelligent Bio Solutions.
Cytosorbents has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.63, suggesting that its share price is 363% more volatile than the S&P 500.
Cytosorbents received 440 more outperform votes than Intelligent Bio Solutions when rated by MarketBeat users.
Intelligent Bio Solutions has lower revenue, but higher earnings than Cytosorbents.
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Cytosorbents beats Intelligent Bio Solutions on 10 of the 16 factors compared between the two stocks.
Get Intelligent Bio Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intelligent Bio Solutions Competitors List
Related Companies and Tools
This page (NASDAQ:INBS) was last updated on 3/30/2025 by MarketBeat.com Staff
Buy INBS Stock Free INBS Stock Alerts